Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

accounts for 1.7% of all cancer-related deaths. Neuroendocrine carcinoma of the gallbladder (GB-NEC) is a rare subtype of GBC that is more malignant than GBC. Small-cell neuroendocrine carcinoma of ...

Woese Institute for Genomic Biology, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States Pancreatic neuroendocrine ... activator PAC-1 enhances PNET cell death in cell ...

Background: Rectal neuroendocrine tumors (NET) are thought to originate from the diffuse neuroendocrine system. The lack of apparent signs of illness and the patient’s non-specific presentations often ...

Median PFS among 99 patients with pNET who were randomized 2:1 to receive cabozantinib or ... progression…regardless of primary tumor site and grade. Sharon Worcester, MA, is an award-winning ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine ... Cancer Network updated its guidelines to recommend Cabometyx as a category 1 ...

NET are heterogeneous tumors that arise from the neuroendocrine ... in 1% of CABOMETYX patients. Monitor for signs and symptoms, and discontinue CABOMETYX in patients with Grade 4 fistulas or ...

1 The drug is indicated to treat ... clinical director of the Gastrointestinal Cancer Center and Director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer Institute ...